Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Operating Expenses (2024 - 2025)

Indivior Pharmaceuticals has reported Other Operating Expenses over the past 2 years, most recently at -$2.0 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at -$2.0 million for Q4 2025, down 300.0% from a year ago — trailing twelve months through Dec 2025 was -$3.0 million (up 98.46% YoY), and the annual figure for FY2025 was -$3.0 million, up 98.46%.
  • Other Operating Expenses for Q4 2025 was -$2.0 million at Indivior Pharmaceuticals, down from -$1.0 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for INDV hit a ceiling of $1.0 million in Q4 2024 and a floor of -$160.0 million in Q2 2024.